23.42
+0.11(+0.47%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
2638
First IPO Date
June 01, 2009
| Name | Title | Pay | Year Born |
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & Chief Executive Officer | 3.07M | 1961 |
| Mr. Martin Schultz | Senior Director of Clinical Operations & Non-Independent Director | 210,799 | 1977 |
| Dr. Mijke Zachariasse Ph.D. | Senior Director, Head of Antibody Research Materials & Non-Independent Director | 240,914 | 1974 |
| Ms. Birgitte Stephensen M.Sc. | Executive Vice President & Chief Legal Officer | 737,798 | 1961 |
| Mr. Rayne Waller | Executive Vice President & Chief Technical Operations Officer | 764,901 | 1968 |
| Dr. Martine J. van Vugt Ph.D. | Executive Vice President & Chief Strategy Officer | 782,969 | 1971 |
| Mr. Christopher Cozic | Executive Vice President & Chief People Officer | 828,141 | 1979 |
| Mr. Anthony Pagano CPA | Executive Vice President & Chief Financial Officer | 1.13M | 1978 |
| Dr. Tahamtan Ahmadi M.D., Ph.D. | Executive Vice President, Chief Medical Officer & Head of Experimental Medicines | 1.19M | 1973 |
| Dr. Judith V. Klimovsky M.D. | Executive Vice President & Chief Development Officer | 1.28M | 1958 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.